Description
This report, IVD in China represents Kalorama’s complete analysis on the Chinese IVD market. The report provides an introduction to the healthcare system in China, the results of recent reform efforts, and issues and trends. Regional breakouts of the Chinese system are provided. The report describes the role that out-of-pocket expenditures and private concerns play in the delivery of healthcare in the nation.
The modern Chinese healthcare market was borne of and continues to be guided by the progressive intentions of the central government of the People’s Republic of China. The government’s liberalization of the mainland Chinese economy beginning in the 1970s was accompanied by the elimination of long-standing and costly healthcare schemes and other social safety nets. IVD is an important part of the healthcare system and the industry has been impacted by the changes described in this report.
As part of its analysis, Market Size and Forecasts for Key IVD Markets including:
• Clinical Chemistry
• Microbiology, ID/AST and Molecular
• Point of Care Testing
• Immunoassays
• Urinalysis
• Molecular Testing
• Coagulation
• Histology
• Hematology
• Blood Testing and Typing
• Flow Cytometry
More affluent Chinese were also introduced to health problems associated with the adoption of new lifestyles associated with urbanization and greater discretionary income in opened consumer markets. Rising life expectancy and the one-child policy have accelerated demographic aging in China, representing another major long-term trend guiding increased healthcare demand. In short, China is confronted by a host of continuing and novel structural challenges to the accessibility and provision of modern healthcare for its demographically diverse, geographically dispersed, and economically stratified populace.
While private sector hospitals and clinics’ role in the formation of the contemporary Chinese healthcare sector is notable, China’s central, regional and local governments have been the greatest factor behind exceptional growth in the Chinese healthcare market. The central government has initiated pivotal investment strategies with public funds to drive infrastructural expansion, mediated relations between multinational companies and domestic industry, and controlled access to domestic distribution channels and Chinese patients. Central planning, other regulatory controls and regional investment on the part of provincial and local governments have also guided extraordinary growth in healthcare markets that include leading domestic markets in Beijing, Shanghai, Guangzhou, Shenzhen and Hong Kong as well as newly-developed and booming regional markets in China’s growing domestic economy.
The report provides coverage of key Issues and Trends in the market, and details competitors in the IVD industry. As part of its coverage, the following companies are profiled:
• Affymetrix, Inc.
• Axis-Shield plc
• Biohit Oy
• Hologic, Inc.
• IRIS International, Inc.
• Life Technologies Corporation
• Luminex Corporation
• MedMira
• Novartis Diagnostics
• PerkinElmer
• Promega Corporation
• Phadia AB
• QIAGEN N.V.
• Siemens Healthcare Diagnostics
• SuperNova Diagnostics, Inc.
• Chinese IVD Companies – Recent Activity
• CapitalBio Corporation
• Caretium Medical Instruments
• Chemtron Biotech Co. Ltd.
• China Health Labs & Diagnostics Ltd.
• Daan Gene Co. Ltd.
• Shanghai Fosun Pharmaceutical Co. Ltd.
• Hai Kang Life Corporation
• Beijing Leadman Biochemistry Co. Ltd.
• Mindray Medical International Ltd.
Table of Contents
- CHAPTER ONE: EXECUTIVE SUMMARYIntroduction
- China in Context – A Developing Economy with First-World Problems
- Demographics and Aging
- Disease Drivers
- Infectious Disease Threats
- IVD Market in China
- Chinese Healthcare Reform and Hospital Infrastructure
- Market Barriers – Regulation, Policy and Distribution
- Regulation and Policy Challenges for International Companies
- Distribution in China
- Major Findings of the Report
- CHAPTER TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD – CHINA IN CONTEXTBackground
- Population Trends and Disease Demographics
- Disease Trends
- Diabetes
- Cancer
- Allergy
- Cardiovascular Disease
- Emerging Viruses and Diseases
- Market Segment Opportunities
- Point-of-Care (POC) Testing
- Clinical Labs
- Research and High Technology
- The Future of Chinese Economic Growth
- BRIC Metrics – Chinese IVD Market in Context
- Available Markets – Urban Populations in BRIC Countries
- Paying for Healthcare – Government Expenditures and the Culture of Spending
- Healthcare Capacities in BRIC Nations – A Work in Progress
- IVD Spending
- Will China Capture the IVD Industry?
- CHAPTER THREE: CHINA IVD MARKET SIZE AND SWOT ANALYSISIntroduction
- The Market
- Strengths – Available Market, Infrastructure Expansion and Challenging Disease
- Burdens
- Weaknesses – factors that offer barriers to market success and entry
- Insurance
- Regulation – Product Approval and Clinical Trials
- Regulation – Healthcare Service Cost Controls
- Distribution Challenges
- Opportunities – Rural Healthcare and Technology Partnerships
- Threats – Domestic Competition and Government Policy
- CHAPTER FOUR: INDUSTRY AND COMPANY ACTIVITY IN CHINAIntroduction
- Affymetrix, Inc.
- Axis-Shield plc
- Biohit Oy
- Hologic, Inc.
- IRIS International, Inc.
- Life Technologies Corporation
- Luminex Corporation
- MedMira
- Novartis Diagnostics
- PerkinElmer
- Promega Corporation
- Phadia AB
- QIAGEN N.V.
- Siemens Healthcare Diagnostics
- SuperNova Diagnostics, Inc.
- Chinese IVD Companies – Recent Activity
- CapitalBio Corporation
- Caretium Medical Instruments
- Chemtron Biotech Co. Ltd.
- China Health Labs & Diagnostics Ltd.
- Daan Gene Co. Ltd.
- Shanghai Fosun Pharmaceutical Co. Ltd.
- Hai Kang Life Corporation
- Beijing Leadman Biochemistry Co. Ltd.
- Mindray Medical International Ltd.
L I S T O F E X H I B I T S
- CHAPTER ONE: EXECUTIVE SUMMARYTable 1-1: IVD Sales in China by Market Segment (Immunoassays, Clinical
- Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other)
- Table 1-2: BRIC IVD Markets by Country, 2012-2017
- CHAPTER TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD – CHINA IN CONTEXTTable 2-1: Elderly Support Ratio in China, Other BRIC and
- Selected Countries (2010/2050)
- Table 2-2: Selected Worldwide Disease Statistics
- Table 2-3: Clinical Lab Counts and Lab Automation Penetration in
- BRIC Countries
- Table 2-4: Available (Urban) Market Development in BRIC Countries
- (2003-2012)
- Table 2-5: Government and Total Health Expenditures in BRIC and
- Comparison Countries (% of GDP and $ Billions)
- Table 2-6: Growth Rates of Government and Total Healthcare Expenditures
- and Real GDP (BRIC and Comparison Countries; 2003-2012)
- Table 2-7: Healthcare System Capacities – BRIC and Comparison Countries
- Table 2-8: Per Capita IVD Expenditures and IVD Markets by Country, 2012
- Table 2-9: BRIC IVD Markets by Country, 2012-2017
- Table 2-10 Selected Made-in-China Lab Supplies
- CHAPTER THREE: CHINA IVD MARKET SIZE AND SWOT ANALYSISTable 3-1: IVD Sales in China by Market Segment (Immunoassays,
- Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other)
- Table 3-2: Out-Of-Pocket, Other Private and Government Healthcare
- Expenditures in BRIC and Comparison Countries (% of Total Expenditures)
- Figure 3-1: Chinese Urban Healthcare Market by National Market Shares of
- Province/Direct-Controlled Municipality
- Figure 3-2: Chinese Rural Healthcare Market by National Market Shares of
- Province/Direct-Controlled Municipality
- CHAPTER FOUR: INDUSTRY AND COMPANY ACTIVITY IN CHINATable 4-1: Leading IVD Companies in China
- Table 4-2: Other IVD Companies in China
- Table 4-3: Chinese IVD Companies at the AACC’s 2012 LabExpo
